PL3445406T3 - Kompozycje i sposoby zwiększonej ekspresji genów PKLR - Google Patents

Kompozycje i sposoby zwiększonej ekspresji genów PKLR

Info

Publication number
PL3445406T3
PL3445406T3 PL17786662T PL17786662T PL3445406T3 PL 3445406 T3 PL3445406 T3 PL 3445406T3 PL 17786662 T PL17786662 T PL 17786662T PL 17786662 T PL17786662 T PL 17786662T PL 3445406 T3 PL3445406 T3 PL 3445406T3
Authority
PL
Poland
Prior art keywords
pklr
compositions
methods
gene expression
enhanced gene
Prior art date
Application number
PL17786662T
Other languages
English (en)
Inventor
Jose C. SEGOVIA
Maria G. GOMEZ
Susana NAVARRO
Nestor MEZA
Juan Bueren
Maria G. BRAVO
Original Assignee
Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas, O.A., M.P.
Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Consorcio Centro de Investigación Biomédica en Red, M.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas, O.A., M.P., Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz, Consorcio Centro de Investigación Biomédica en Red, M.P. filed Critical Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas, O.A., M.P.
Publication of PL3445406T3 publication Critical patent/PL3445406T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/0104—Pyruvate kinase (2.7.1.40)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17786662T 2016-04-20 2017-04-20 Kompozycje i sposoby zwiększonej ekspresji genów PKLR PL3445406T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325397P 2016-04-20 2016-04-20
PCT/US2017/028695 WO2017184903A1 (en) 2016-04-20 2017-04-20 Compositions and methods for enhanced gene expression of pklr
EP17786662.1A EP3445406B1 (en) 2016-04-20 2017-04-20 Compositions and methods for enhanced gene expression of pklr

Publications (1)

Publication Number Publication Date
PL3445406T3 true PL3445406T3 (pl) 2022-02-07

Family

ID=60116402

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17786662T PL3445406T3 (pl) 2016-04-20 2017-04-20 Kompozycje i sposoby zwiększonej ekspresji genów PKLR

Country Status (17)

Country Link
US (3) US11286501B2 (pl)
EP (1) EP3445406B1 (pl)
JP (3) JP7045362B2 (pl)
KR (3) KR102673203B1 (pl)
CN (2) CN109641063B (pl)
AU (3) AU2017254665C1 (pl)
BR (1) BR112018071695A2 (pl)
CA (1) CA3021572A1 (pl)
DK (1) DK3445406T3 (pl)
ES (1) ES2885833T3 (pl)
HU (1) HUE055862T2 (pl)
IL (1) IL262459B2 (pl)
MX (1) MX382997B (pl)
PL (1) PL3445406T3 (pl)
PT (1) PT3445406T (pl)
SG (1) SG11201809096VA (pl)
WO (1) WO2017184903A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7045362B2 (ja) * 2016-04-20 2022-03-31 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． Ｐｋｌｒの遺伝子発現増強のための組成物および方法
KR102726267B1 (ko) * 2017-10-16 2024-11-11 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. 피루베이트 키나제 결핍증을 치료하기 위한 pklr 전달용 렌티바이러스 벡터
JP7576754B2 (ja) * 2018-04-11 2024-11-01 スペースクラフト セブン リミテッド ライアビリティ カンパニー 幹細胞移植のための組成物および方法
US12378576B2 (en) 2018-04-27 2025-08-05 Spacecraft Seven, Llc Gene therapy for CNS degeneration
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3185267A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE123059T1 (de) 1987-09-17 1995-06-15 Massachusetts Inst Technology Menschliche, erythroid-spezifische transkriptionsenhancer.
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6607879B1 (en) 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6822112B1 (en) 1999-08-13 2004-11-23 Taisho Pharmaceutical Co., Ltd. Prostaglandin derivatives
PT1792997E (pt) 1999-10-12 2012-02-02 Pasteur Institut Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral
DE19960113A1 (de) 1999-12-08 2001-06-13 Wita Proteomics Ag Mittel und Verfahren zur Diagnose von Lyme Borreliose sowie Borreliose-Impfstoff
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
GB0024550D0 (pl) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
KR20040054699A (ko) 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물
WO2003066086A2 (en) 2002-02-04 2003-08-14 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostatis
NZ536899A (en) 2002-05-02 2008-04-30 Univ Rochester Vectors having both isoforms of beta-hexosaminidase
JP2006524051A (ja) 2003-04-24 2006-10-26 フォンダッチォーネ・セントロ・サン・ラファエル・デル・モンテ・タボール 両方向性合成プロモーターを備えたレンチウイルスベクターおよびその使用
JP2007054069A (ja) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
BE1016793A4 (fr) 2005-10-04 2007-06-05 Artelis Procede de culture de cellules et dispositif permettant sa mise en oeuvre.
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
ES2325711B1 (es) 2007-04-17 2010-06-17 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (Ciemat) Vectores de expresion que comprenden el promotor del gen pklr humano y su uso para la elaboracion de composiciones farmaceuticas destinadas a terapia genica somatica con expresion especifica en celulas eritroides.
WO2008136670A2 (en) 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
EP2152889B1 (en) 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
DK2520643T3 (da) 2007-12-07 2020-01-20 Miltenyi Biotec Bv & Co Kg Prøvebehandlingssystemer og -fremgangsmåder
DE102008063606A1 (de) 2008-12-18 2010-06-24 Eufets Ag Ein-Vektor Tet-System und dessen Verwendung
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
DE102009021592A1 (de) 2009-05-15 2010-11-18 Medizinische Hochschule Hannover ASLV-Vektorsystem
WO2011043719A1 (en) 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
DE102010003419B4 (de) * 2010-03-30 2019-09-12 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von L-Ornithin
US20140377288A1 (en) * 2011-09-16 2014-12-25 The Board Of Regents Of The University Of Texas System Compositions and methods related to dna damage repair
DK3763820T3 (da) 2012-02-29 2022-02-07 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Retroviral transduktion ved hjælp af poloxamerer
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
CN105229139B (zh) 2012-12-11 2018-02-13 颇尔科技英国有限公司 用于细胞培养的器皿
CN105658796B (zh) * 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
EP2935581A4 (en) 2012-12-21 2016-07-27 Merck Sharp & Dohme EXPRESSION VECTORS FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
GB201318347D0 (en) 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
EP3068440B1 (en) 2013-11-15 2020-01-08 Northwestern University Inhibition of oxidative stress in atrial fibrillation
JP2017514476A (ja) 2014-05-01 2017-06-08 ユニバーシティ・オブ・ワシントン アデノウイルスベクターを用いたインビボでの遺伝子操作
WO2015188191A1 (en) 2014-06-06 2015-12-10 Wong Wilson W Dna recombinase circuits for logical control of gene expression
CN104020298A (zh) 2014-06-12 2014-09-03 中国科学院化学研究所 自供能量的微管-驱动蛋白运输体系及其制备方法
GB201417042D0 (en) 2014-09-29 2014-11-12 Fkd Therapies Oy Method
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
MA41506A (fr) 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
WO2016145217A1 (en) 2015-03-10 2016-09-15 The Trustees Of Columbia University In The City Of New York Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
AU2016348782A1 (en) 2015-11-05 2018-05-31 Cellectis Process of gene-editing of cells isolated from a subject suffering from a metabolic disease affecting the erythroid lineage, cells obtained by said process and uses thereof.
KR20180069081A (ko) 2015-11-11 2018-06-22 인트렉손 코포레이션 심장 이상 및 기타 병리 이상의 치료를 위한 복수의 생물학적으로 활성화된 폴리펩티드를 단일 벡터로부터 발현하기 위한 조성물 및 방법
KR20180102172A (ko) 2016-01-19 2018-09-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 다논병 및 다른 자가포식 장애의 치료 방법
EP3411059A4 (en) 2016-02-02 2019-10-16 University Of Massachusetts METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
ES2992295T3 (es) 2016-02-12 2024-12-11 Bluebird Bio Inc Composiciones potenciadoras de Vcn y métodos de uso de las mismas
LT3722436T (lt) 2016-04-14 2025-11-10 Fiksuoto lovio bioreaktorius su nuolatinio srauto siurbliu / vamzdžių sistema
JP7045362B2 (ja) 2016-04-20 2022-03-31 セントロ デ インベスティガシオンス エネルジェチカス メディオアンビエンタゥス イェ テクノロジカス オー．エイ． エム．ピー． Ｐｋｌｒの遺伝子発現増強のための組成物および方法
WO2017218519A1 (en) 2016-06-13 2017-12-21 Bluebird Bio, Inc. Gene therapy of neuronal ceroid lipofuscinoses
WO2017218948A2 (en) 2016-06-17 2017-12-21 Fred Hutchinson Cancer Research Center Strategies to assess and/or produce cell populations with predictive engraftment potential
EP3510162A4 (en) 2016-09-08 2020-02-19 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. GENE THERAPY FOR PATIENTS WITH FANCONI ANEMIA
US20200071721A1 (en) 2016-12-06 2020-03-05 Bluebird Bio, Inc. Gene therapy for mucopolysaccharidosis, type ii
CN110214182A (zh) 2016-12-06 2019-09-06 蓝鸟生物公司 用于i型黏多糖贮积症的基因治疗
US20180326022A1 (en) 2017-04-21 2018-11-15 The Trustees Of The University Of Pennsylvania Compositions and methods for improving heart function and treating heart failure
WO2018201065A1 (en) 2017-04-27 2018-11-01 Fred Hutchinson Cancer Research Center Therapeutic formulations containing cd34+ stem cells derived from negative selection
KR102726267B1 (ko) 2017-10-16 2024-11-11 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. 피루베이트 키나제 결핍증을 치료하기 위한 pklr 전달용 렌티바이러스 벡터
JP7576754B2 (ja) 2018-04-11 2024-11-01 スペースクラフト セブン リミテッド ライアビリティ カンパニー 幹細胞移植のための組成物および方法
US12378576B2 (en) 2018-04-27 2025-08-05 Spacecraft Seven, Llc Gene therapy for CNS degeneration
MX2021000443A (es) 2018-07-12 2021-05-28 Spacecraft Seven Llc Vectores de terapia génica para el tratamiento de la enfermedad de danon.
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
EP3836956A4 (en) 2018-08-16 2022-05-18 Spacecraft Seven, LLC Production methods for viral vectors
KR20210125999A (ko) 2019-02-12 2021-10-19 스페이스크래프트 세븐, 엘엘씨 다논병 치료를 위한 유전자 요법 벡터
CA3137700A1 (en) 2019-05-23 2020-11-26 Brian Beard Gene therapy vectors for infantile malignant osteopetrosis
WO2021236981A2 (en) 2020-05-20 2021-11-25 Spacecraft Seven, Llc Engineered parkin and uses thereof
WO2022017630A1 (en) 2020-07-23 2022-01-27 Ucl Business Ltd GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
EP4192960A4 (en) 2020-08-05 2024-11-27 Spacecraft Seven, LLC ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF
CA3184983A1 (en) 2020-08-05 2022-02-10 Christopher Dean HERZOG Csrp3 (cysteine and glycine rich protein 3) gene therapy
CA3185267A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
IL303428A (en) 2020-12-07 2023-08-01 Spacecraft Seven Llc Treatment of danon disease
EP4444892A2 (en) 2021-12-08 2024-10-16 Spacecraft Seven, LLC Junctophilin-2 (jph2) gene therapy using aav vector
EP4444893A1 (en) 2021-12-10 2024-10-16 Spacecraft Seven, LLC Troponin c (tnnc1) gene therapy using aav vector
AU2023217712A1 (en) 2022-02-08 2024-08-08 Spacecraft Seven, Llc Adeno-associated viral vector for glut1 expression and uses thereof
CN119072323A (zh) 2022-04-22 2024-12-03 航天七号有限责任公司 使用aav载体的b细胞淋巴瘤2关联永生基因3(bag3)基因疗法

Also Published As

Publication number Publication date
BR112018071695A2 (pt) 2019-02-19
AU2021200872B2 (en) 2024-04-04
PT3445406T (pt) 2021-08-30
DK3445406T3 (da) 2021-08-30
IL262459B2 (en) 2025-10-01
RU2018140783A (ru) 2020-05-20
US20190284573A1 (en) 2019-09-19
MX382997B (es) 2025-03-13
CA3021572A1 (en) 2017-10-26
EP3445406B1 (en) 2021-05-26
CN116179580A (zh) 2023-05-30
US20220177920A1 (en) 2022-06-09
US12163151B2 (en) 2024-12-10
CN109641063A (zh) 2019-04-16
AU2024204597A1 (en) 2024-07-18
JP2019514422A (ja) 2019-06-06
AU2021200872A1 (en) 2021-03-04
SG11201809096VA (en) 2018-11-29
KR20220147607A (ko) 2022-11-03
KR102440880B1 (ko) 2022-09-06
US11286501B2 (en) 2022-03-29
IL262459B1 (en) 2025-06-01
HUE055862T2 (hu) 2021-12-28
KR102673203B1 (ko) 2024-06-10
RU2018140783A3 (pl) 2020-08-17
KR20240096679A (ko) 2024-06-26
JP2022101543A (ja) 2022-07-06
KR20190053136A (ko) 2019-05-17
KR102821903B1 (ko) 2025-06-18
CN109641063B (zh) 2022-11-15
JP2024150536A (ja) 2024-10-23
US20250215454A1 (en) 2025-07-03
MX2018012872A (es) 2019-08-22
EP3445406A4 (en) 2019-12-25
JP7522782B2 (ja) 2024-07-25
WO2017184903A1 (en) 2017-10-26
AU2017254665C1 (en) 2021-03-11
AU2017254665B2 (en) 2020-11-12
EP3445406A1 (en) 2019-02-27
ES2885833T3 (es) 2021-12-15
AU2017254665A1 (en) 2018-11-22
JP7045362B2 (ja) 2022-03-31
IL262459A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
IL290566A (en) Preparations and methods for preventing lipoprotein A gene expression
HUS2200011I1 (hu) Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására
IL273875A (en) Methods and compounds for inhibiting expression of LDHA
IL249637B (en) Methods and compositions for targeted genetic modifications and methods for use
IL254518A0 (en) Preparations and methods for suppressing the expression of the factor xii gene
IL321463A (en) Compositions and methods for inhibiting expression of the alas1 gene
IL255998A (en) Preparations and methods for suppressing the expression of the hif2alpha strain
EP3105327A4 (en) Compositions and methods of using microrna inhibitors
PL3445406T3 (pl) Kompozycje i sposoby zwiększonej ekspresji genów PKLR
EP3237619B8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
EP3191186A4 (en) Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
HK40001448A (en) Compositions and methods for enhanced gene expression of pklr
HK40021851A (en) Compositions and methods for enhanced gene expression
AU2014904383A0 (en) Compositions and methods for the delivery of agents that inhibit gene expression